Replies to post #148648 on Vivos Inc (RDGL)

[Hondo44]

Actually it happened around July 15th with the sale of 15 million shares in the Reg A.

It was 342,743,915 on or about 7/5/22

It's now 357,743,915

[konshe]

In OTC market, Dilution 12mm shares means nothing.

[SC8]

As others have mentioned dilution was 15 million shares. This raised ~$1.2 million. RDGL now has ~10 months cash on hand which is good news. There's also ~50 million remaining unexpired warrants of ~$0.067/share average, which I sure hope are exercised. And it looks like the remaining 35 million shares from current Reg A are being held back for a post IDE approval offering, although I wouldn't be surprised if some or all were sold as a hedge into speculation after IDE submission, as was done into the BDD speculation.

So current share count + warrants expected to be exercised upon IDE approval + remaining Reg A = ~443 million share count expected post IDE approval.

Then assuming remaining Reg A shares come with warrants and positive initial human trial data a couple years post IDE approval (or sooner, depending on patient recruitment), would bring share count to ~478 million before an expected offering to fund larger human trials. Of course, RDGL would be a buyout candidate at that point.